B. Metzler seel. Sohn & Co. AG Increases Stock Position in HealthEquity, Inc. $HQY

Key Points

• B. Metzler seel. Sohn & Co. AG increased its stake in HealthEquity (NASDAQ:HQY) by 23.5%, buying 19,772 shares to own 104,078 shares (about 0.12% of the company) valued at roughly $9.54 million.
• HealthEquity topped expectations in its most recent quarter with EPS of $0.95 vs. $0.90 expected and revenue of $334.6M (up 7.3% year-over-year), reporting a net margin of 16.39% and ROE of 13.86%.
• Analysts have been upgrading the stock (notably BMO, KeyCorp and Deutsche Bank raising price targets), and MarketBeat shows a consensus rating of Moderate Buy with a consensus price target of $111.79.

B. Metzler seel. Sohn & Co. AG boosted its stake in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 23.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 104,078 shares of the company's stock after purchasing an additional 19,772 shares during the quarter. B. Metzler seel. Sohn & Co. AG owned about 0.12% of HealthEquity worth $9,535,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. True Wealth Design LLC raised its stake in HealthEquity by 3,522.2% in the third quarter. True Wealth Design LLC now owns 326 shares of the company's stock valued at $31,000 after purchasing an additional 317 shares in the last quarter. Farther Finance Advisors LLC raised its stake in HealthEquity by 59.3% in the third quarter. Farther Finance Advisors LLC now owns 392 shares of the company's stock valued at $37,000 after purchasing an additional 146 shares in the last quarter. AlphaQuest LLC raised its stake in HealthEquity by 52.2% in the third quarter. AlphaQuest LLC now owns 624 shares of the company's stock valued at $59,000 after purchasing an additional 214 shares in the last quarter. Larson Financial Group LLC raised its stake in HealthEquity by 24.4% in the third quarter. Larson Financial Group LLC now owns 628 shares of the company's stock valued at $60,000 after purchasing an additional 123 shares in the last quarter. Finally, IFP Advisors Inc raised its stake in HealthEquity by 1,602.3% in the third quarter. IFP Advisors Inc now owns 749 shares of the company's stock valued at $75,000 after purchasing an additional 705 shares in the last quarter. 99.55% of the stock is owned by hedge funds and other institutional investors.

HealthEquity Stock Down 6.2%

Shares of HealthEquity stock opened at $77.75 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.27 and a current ratio of 3.27. HealthEquity, Inc. has a 52-week low of $72.76 and a 52-week high of $116.65. The stock has a market capitalization of $6.57 billion, a price-to-earnings ratio of 31.61, a P/E/G ratio of 1.51 and a beta of 0.26. The company's 50 day moving average price is $80.26 and its 200-day moving average price is $88.32.

HealthEquity (NASDAQ:HQY - Get Free Report) last issued its earnings results on Tuesday, March 17th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.05. HealthEquity had a net margin of 16.39% and a return on equity of 13.86%. The firm had revenue of $334.59 million for the quarter, compared to analysts' expectations of $332.48 million. The business's quarterly revenue was up 7.3% compared to the same quarter last year. Equities research analysts forecast that HealthEquity, Inc. will post 3.84 EPS for the current year.

Analyst Ratings Changes

HQY has been the topic of a number of recent research reports. BMO Capital Markets upgraded shares of HealthEquity from a "market perform" rating to an "outperform" rating and increased their price target for the company from $85.00 to $105.00 in a research report on Thursday, April 9th. KeyCorp increased their price target on shares of HealthEquity from $120.00 to $125.00 and gave the company an "overweight" rating in a research report on Thursday, January 8th. Deutsche Bank Aktiengesellschaft increased their price target on shares of HealthEquity from $120.00 to $128.00 and gave the company a "buy" rating in a research report on Thursday, March 19th. Weiss Ratings reiterated a "hold (c+)" rating on shares of HealthEquity in a research report on Thursday, January 22nd. Finally, Barrington Research reduced their price target on shares of HealthEquity from $125.00 to $110.00 and set an "outperform" rating on the stock in a research report on Wednesday, March 18th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, HealthEquity has a consensus rating of "Moderate Buy" and a consensus price target of $111.79.

HealthEquity Profile

HealthEquity, Inc NASDAQ: HQY is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.

Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HealthEquity, Inc. (NASDAQ:HQY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.